Granite Creek Capital Partners LLC
09/08/2021 | Press release | Archived content
Royal Biologics Announces FDA Approval of the Maxx™ Concentration System.
Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, has announced FDA 510K approval of their Maxx™-PRP concentration system. Maxx™-PRP is a patented next-generation concentration device that can be used to concentrate autologous whole blood for the safe and rapid preparation of platelet-rich plasma to use point of care for mixing with autograft and/or allograft to improve handling characteristics. Royal's Maxx™-PRP system offers "customizable formulations" of platelet-rich plasma, allowing clinicians to treat a variety of conditions in orthopedics, sports medicine, plastic surgery and regenerative medicine.
Granite Creek Capital Partners LLC published this content on September 08, 2021, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 10, 2026 at 09:59 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]